About Us

Ovensa Inc. works with pharmaceutical companies to enhance the stability and delivery of their RNA therapeutics, antibodies or peptides for vaccine and CNS applications. The company leverages its proprietary Trimethyl Chitosan (TRIOZAN™) and ligand targeting platforms to overcome drug delivery challenges such as crossing the mucosal and blood-brain barriers, cell targeting, payload internalization and endosomal escape.

The company is also developing a siRNA candidate to reduce the overexpression of Galectin-1. Preclinical studies have shown that its siRNA/Gal-1 candidate synergistically improves the efficacy of temozolomide and an anti-PD1 in recurrent glioblastoma.